The United States Food and Drug Administration has approved a cheaper generic version of lenacapavir, the long-acting injection used to prevent HIV that is administered just twice a year, Indian drugmaker Dr. Reddy's Laboratories announced on Monday. The move is expected to improve access to the medicine in low-income countries, where the cost of newer prevention tools has long kept them out of reach for many people at higher risk of infection. Under a pricing agreement reached in 2025, the generic is targeted to be supplied in 120 countries at 40 US dollars per person per year. Lenacapavir was originally developed by the US pharmaceutical company Gilead, and its arrival in affordable generic form is being seen as one of the most closely watched developments in the global effort to reduce new HIV infections, as reported by RatoPati.

A twice-yearly option for HIV prevention

Lenacapavir stands apart from most HIV prevention medicines because of its dosing schedule. A single injection provides protection for six months, meaning people only need two clinic visits a year to stay covered. By contrast, conventional pre-exposure prophylaxis, commonly known as PrEP, usually relies on oral tablets that must be taken every day. Public health specialists have long identified daily adherence as one of the biggest weaknesses of that approach, since missed doses lower the level of protection and the routine of taking a pill daily can be difficult to sustain, particularly for people who face stigma or who would prefer not to keep HIV prevention medication visible at home.

A twice-yearly injection changes that equation in several ways:

  • Continuity of protection - once administered, the injection works for six months, removing the risk of protection lapsing because of forgotten doses.
  • Reduced stigma - people do not need to store or take daily medication that may reveal their prevention choices to others.
  • Predictable delivery - health systems can plan around two visits a year, pairing injections with HIV testing and counselling.

The FDA approval announced on Monday concerns a generic copy of this medicine, produced with a price point intended for far wider distribution than the originator product alone could achieve.

Dr. Reddy's announcement and the 2025 pricing agreement

Dr. Reddy's Laboratories, one of India's major generic pharmaceutical manufacturers, announced the FDA approval on Monday. The company's announcement ties directly into the 2025 pricing agreement under which lenacapavir is targeted to be supplied across 120 countries at 40 US dollars per person per year. That target price reflects a broader model in global health in which originator companies and generic manufacturers work to supply low- and middle-income countries at sharply reduced rates, making modern medicines affordable for public health budgets and donor-funded programmes.

Generic competition plays an outsized role in the HIV response. Countries with high HIV burdens have long depended on affordable generic antiretrovirals to run large-scale treatment and prevention programmes, and the entry of a generic manufacturer into the prevention space follows that established pattern. FDA clearance also carries weight beyond the United States, as approval from the US regulator is widely regarded as a benchmark of manufacturing quality and is often taken into consideration by other regulators and international procurement bodies when they authorise or purchase medicines.

From Gilead's originator to global supply

Lenacapavir was developed by Gilead, the US company behind several landmark HIV therapies. The journey from an originator product to a broadly affordable generic usually takes considerable time, involving licensing arrangements, regulatory filings in multiple jurisdictions and the build-out of manufacturing capacity capable of serving millions of people. The 2025 pricing agreement, combined with Monday's FDA approval of a generic version, indicates that this pathway for lenacapavir is now moving forward.

For low-income countries, the stakes are significant. Newer biomedical tools for HIV prevention frequently reach wealthier markets first, while communities facing the greatest exposure often wait years for access. The 40-dollar-per-person-per-year target is designed to close that gap, aiming to place a state-of-the-art prevention option within the reach of health systems that have historically had to rely on older, cheaper tools.

What the approval means for the HIV response

The approval carries several implications for the broader fight against HIV:

  • Wider availability - the supply target covers 120 countries, a substantial expansion of where the injection can realistically be offered.
  • Affordability - a price of 40 US dollars per person per year is structured to fit within the budgets of low-income health systems.
  • Simplicity of use - two injections a year offer a practical alternative to daily oral prevention for people who struggle with adherence.
  • Momentum for prevention - long-acting options are increasingly viewed as central to reducing new infections, since they make sustained protection easier to maintain.

Attention will now turn to how quickly the generic reaches clinics in the countries covered by the pricing agreement, and whether manufacturing and distribution can match the ambition of the 120-country target. Monday's announcement marks the regulatory milestone; the next measure of success will be delivery, as health authorities and programme partners work to translate the approval into injections actually reaching the people who need them. For a medicine developed by Gilead and now opening up to generic supply, the approval represents the moment when a major HIV prevention tool begins its shift from innovation to broad public health use.